Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Conditions
Brief summary
This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer. Donor cellular therapy is a short-term transfusion of cells from a family member who is incompletely matched. The use of these partially matched white blood cells may help improve response to standard chemotherapy (cytarabine) and reduce some of the risks of infection, without a permanent transplant. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving donor cellular therapy after cytarabine may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. To assess 2-year disease-free survival (as defined by time to death from any cause or disease relapse, whichever is earlier) for patients \< 60 years of age with intermediate-risk acute myeloid leukemia (AML), in complete remission (CR) after induction chemotherapy, who receive microtransplantation, compared to patients who received consolidation chemotherapy only in a historical published comparable cohort of patients. SECONDARY OBJECTIVES: I. To obtain estimates of rate of relapse, treatment related mortality (TRM), all cause mortality, in the microtransplantation (MST) group and compare it with allogeneic stem cell group (historical cohort). II. To obtain estimates of rate acute graft-versus-host disease (GVHD), chronic GVHD, time to recovery of absolute neutrophil counts and platelets in patients with intermediate risk AML receiving of chemotherapy in combination with microtransplantation. TERTIARY OBJECTIVES: I. Presence or absence of detectable donor chimerism post-microtransplantation until 6 months after the last infusion. II. Characteristics of the infused cells and composition of the graft. III. Dynamics of T-cell clonality. IV. Immune cell subset analysis. OUTLINE: Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine intravenously (IV) over 1-3 hours twice daily (BID) on days -7 to -2 and granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at least every 3 months for 2 years.
Interventions
DRUGCytarabine
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
PROCEDUREPeripheral Blood Stem Cell Transplantation
Undergo microtransplant
BIOLOGICALTherapeutic Allogeneic Lymphocytes
Undergo microtransplant
BIOLOGICALG-CSF mobilized peripheral blood cells
microtransplantation
Sponsors
National Cancer Institute (NCI)
University of Southern California
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 59 Years
Healthy volunteers
No
Inclusion criteria
* PATIENT INCLUSION CRITERIA: * Acute myeloid leukemia-intermediate risk as defined by standard World Health Organization (WHO) criteria for AML (at least 20% blasts in the peripheral blood or bone marrow) at the time of initial diagnosis * Diagnosis of AML according to WHO diagnostic criteria (at least 20% blasts in the peripheral blood or bone marrow), with French-American-British (FAB) classification other than M3 (acute promyelocytic leukemia), documented by bone marrow aspiration and biopsy performed within 14 days prior to administration of 1st dose of remission induction chemotherapy * Intermediate risk based on National Comprehensive Cancer Network (NCCN) * In CR or complete remission with incomplete blood count recovery (CRi) after 1-2 induction chemotherapy documented by a bone marrow examination done within 2 weeks of starting cytarabine in this protocol * Must have achieved CR/CRi with less than 2 induction regimens that contain cytarabine and anthracycline * No 10/10 matched sibling donor available or not financially eligible for allogeneic stem cell transplantation * Must be within 3 months from the last induction regimen at the time of starting cytarabine chemotherapy in this protocol * Patient has at least one medically fit first- or second-degree family member expected to be human leukocyte antigen (HLA) mismatched at 2-9/10 loci; in addition, the prospective donor is willing to voluntarily donate hematopoietic stem cells and sign consent forms * Absolute neutrophil count (ANC) \> 1500, unless due to direct bone marrow involvement of disease * Platelets \> 75,000, unless due to direct bone marrow involvement of disease * Hemoglobin \> 8.0 gm/dL, transfusion allowed * Serum creatinine \< 2.0 x the upper limits of institutional normal (ULN) * Total bilirubin \< 1.5 x the upper limits of institutional normal * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 2.5 x the upper limits of institutional normal (=\< 5 x ULN for patients with suspected liver involvement of leukemia) * Cardiac left ventricular ejection fraction (LVEF) \> 45% * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and estimated survival of at least 3 months * Patients must be able to understand and agree to sign an Institutional Review Board (IRB)-approved informed consent form * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study, and for two months after study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * DONOR INCLUSION CRITERIA: * Donor screening; all donors will meet the standard blood donor criteria established by the participating local blood center, American Association of Blood Banks (AABB) * Donors will be selected from among the subject's relatives, adult children preferred * Infectious disease testing will be done per Hemacare policy and AAAB guidelines * Donor and intended recipient red cell type and compatibility will be determined * Donors will be pre-selected on the basis of HLA haploidentity * If patient is cytomegalovirus (CMV)-negative, donors who are CMV-negative will be preferred; CMV serology of the donor will be tested prior to the allogeneic cell donation; donations from CMV-positive donors to CMV-negative recipients will be given if no CMV negative donor is available, and CMV surveillance and pre-emptive treatment given as per guidelines below
Exclusion criteria
* PATIENT
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival (DFS) | Beginning of therapy to the date of death or the date of last follow-upexamination, assessed at 2 years | The 2-year DFS will be estimated, and the corresponding 90% confidence intervals will be constructed. The data will be displayed using a Kaplan-Meir curve to plot the DFS over time. Calculate bilateral 95% confidential interval of mean difference of disease-free survival rate, and compare the lower limit of the bilateral 95% confidential interval and 15% superiority boundary value. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence acute GVHD, classified as clinically significant (grades 2 to 4) or severe (grades 3 to 4) | 6 months after microtransplant | At single time point, if univariate quantitative data of the meets the normal distribution and homogeneity of variance, perform test of univariate quantitative data, otherwise, adopt the rank-sum test of corresponding design; for univariate quantitative data under multiple time points, use mixed effects model to design variance analysis with repeated measure factors. |
Countries
United States
Outcome results
None listed